comparemela.com
Home
Live Updates
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) : comparemela.com
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization
Related Keywords
Boston ,
Massachusetts ,
United States ,
Matt Pera ,
Inozyme Pharma ,
Stefan Riley ,
Company Or Inozyme ,
Corporate Communications ,
Twitter ,
Nasdaq ,
Inozyme Pharma Inc ,
Facebook ,
Stock Incentive Plan ,
Nasdaq Listing Rule ,
Senior Director ,
comparemela.com © 2020. All Rights Reserved.